• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>One E-Commerce Corporation

One E-Commerce Corporation

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. Alnylam Reports Positive Initial Clinical Activity Results for Givosiran (ALN-AS1), an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias

    Alnylam Reports Positive Initial Clinical Activity Results for Givosiran (ALN-AS1), an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias

  2. Alnylam Reports Positive Interim Clinical Results for Fitusiran from Ongoing Phase 2 Open Label Extension Study in Patients with Hemophilia A or B without Inhibitors

    Alnylam Reports Positive Interim Clinical Results for Fitusiran from Ongoing Phase 2 Open Label Extension Study in Patients with Hemophilia A or B without Inhibitors

  3. Alnylam Reports Positive Interim Phase 1 Results for Fitusiran in Hemophilia A and B Patients with Inhibitors

    Alnylam Reports Positive Interim Phase 1 Results for Fitusiran in Hemophilia A and B Patients with Inhibitors

  4. New Data from ALXN1210 Dose-Escalation Study Presented at ASH Show Rapid and Sustained Reductions in LDH in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

    New Data from ALXN1210 Dose-Escalation Study Presented at ASH Show Rapid and Sustained Reductions in LDH in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

  5. Acetylon Presents Early Phase 1a/1b Results for Citarinostat (ACY-241) in Combination with Pomalyst® and Dexamethasone Showing Promising Treatment Responses in Relapsed or Relapsed-and-Refractory ...

    Acetylon Presents Early Phase 1a/1b Results for Citarinostat (ACY-241) in Combination with Pomalyst® and Dexamethasone Showing Promising Treatment Responses in Relapsed or Relapsed-and-Refractory Multiple Myeloma

  6. Fitch Rates University of Maryland Medical System (MD) 2017 Revs 'A'; Outlook Revised to Negative

    Fitch Rates University of Maryland Medical System (MD) 2017 Revs 'A'; Outlook Revised to Negative

  7. UPDATE: Yes, it's OK to re-gift your unwanted swag this holiday season

    UPDATE: Yes, it's OK to re-gift your unwanted swag this holiday season

  8. Seattle Genetics Presents Data from Phase 2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline Diffuse Large B-cell Lymphoma at ASH Annual Meeting

    Seattle Genetics Presents Data from Phase 2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline Diffuse Large B-cell Lymphoma at ASH Annual Meeting

  9. UPDATE: Yes, it's OK to re-gift your unwanted swag this holiday season

    UPDATE: Yes, it's OK to re-gift your unwanted swag this holiday season

  10. UPDATE: 7 toys you remember from childhood that may be under the tree this year

    UPDATE: 7 toys you remember from childhood that may be under the tree this year

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.